Last reviewed · How we verify
Placebo for ABT-450/r/ABT-267
Placebo for ABT-450/r/ABT-267 is a Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 3 development for Hepatitis C virus infection (control arm in phase 3 trials).
This is a placebo control with no active pharmacological mechanism.
This is a placebo control with no active pharmacological mechanism. Used for Hepatitis C virus infection (control arm in phase 3 trials).
At a glance
| Generic name | Placebo for ABT-450/r/ABT-267 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug ABT-450/r/ABT-267 (a hepatitis C virus NS3/4A protease inhibitor combination). It contains no active pharmaceutical ingredients and serves as a comparator to distinguish true drug effects from natural disease progression or psychological effects.
Approved indications
- Hepatitis C virus infection (control arm in phase 3 trials)
Common side effects
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PHASE3)
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for ABT-450/r/ABT-267 CI brief — competitive landscape report
- Placebo for ABT-450/r/ABT-267 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI
Frequently asked questions about Placebo for ABT-450/r/ABT-267
What is Placebo for ABT-450/r/ABT-267?
How does Placebo for ABT-450/r/ABT-267 work?
What is Placebo for ABT-450/r/ABT-267 used for?
Who makes Placebo for ABT-450/r/ABT-267?
What development phase is Placebo for ABT-450/r/ABT-267 in?
Related
- Manufacturer: AbbVie (prior sponsor, Abbott) — full pipeline
- Therapeutic area: All drugs in Hepatology
- Indication: Drugs for Hepatitis C virus infection (control arm in phase 3 trials)
- Compare: Placebo for ABT-450/r/ABT-267 vs similar drugs
- Pricing: Placebo for ABT-450/r/ABT-267 cost, discount & access